Previous Speakers | Kisaco Research

Previous Speakers

Microbiome Connect: USA 2024
12-14 November, 2024
BOSTON, USA

Previous Trailblazing Speakers

  • Author:

    Chris McChalicher

    Vice President, CMC Technical Development
    Seres Therapeutics

    Chris McChalicher

    Vice President, CMC Technical Development
    Seres Therapeutics
  • Author:

    Ken Blount

    VP of Microbiome Research, Ferring Pharmaceuticals, and CSO, Rebiotix Inc., a Ferring Company

    Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.

    Ken Blount

    VP of Microbiome Research, Ferring Pharmaceuticals, and CSO, Rebiotix Inc., a Ferring Company

    Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.

  • Author:

    Terri Young

    Executive Vice President, Chief Commercial and Strategy Officer
    Seres Therapeutics

    Terri Young

    Executive Vice President, Chief Commercial and Strategy Officer
    Seres Therapeutics
  • Author:

    Trent Munro

    Senior Vice President of Therapeutics
    Microba Life Sciences

    Trent Munro

    Senior Vice President of Therapeutics
    Microba Life Sciences
  • Author:

    Staffan Stromberg

    Chief Executive Officer
    Infant Bacterial Therapeutics

    Staffan Stromberg

    Chief Executive Officer
    Infant Bacterial Therapeutics
  • Author:

    Hervé Affagard

    Chief Executive Officer
    MaaT Pharma

    Hervé Affagard

    Chief Executive Officer
    MaaT Pharma
  • Author:

    Daniel Cuoto

    Chief Operating Officer
    Vedanta Bio

    Daniel Cuoto

    Chief Operating Officer
    Vedanta Bio
  • Author:

    Nikole Kimes

    Chief Executive Officer
    Siolta Therapeutics

    Nikole Kimes

    Chief Executive Officer
    Siolta Therapeutics
  • Author:

    Denise Kelly

    Investment Advisor
    Seventure Partners

    Denise Kelly

    Investment Advisor
    Seventure Partners
  • Author:

    Caroline Mitchell

    Professor
    Harvard University

    Caroline Mitchell

    Professor
    Harvard University
  • Author:

    Andrew Nealon

    Partner and Chief Analyst
    Joyance

    Andrew Nealon

    Partner and Chief Analyst
    Joyance
  • Author:

    Bharat Dixit

    Chief Technology Officer
    Adiso Therapeutics

    Bharat Dixit

    Chief Technology Officer
    Adiso Therapeutics
  • Author:

    Paul Carlson

    Principal Investigator
    FDA

    Paul Carlson

    Principal Investigator
    FDA
  • Author:

    Ellen Turner

    Medical Officer
    FDA - Center for Biologics Evaluation and Research, Office of Vaccines Research

    Ellen Turner

    Medical Officer
    FDA - Center for Biologics Evaluation and Research, Office of Vaccines Research
  • Author:

    Benjamin Hadida

    Chief Executive Officer
    Exeliom Biosciences

    Benjamin Hadida

    Chief Executive Officer
    Exeliom Biosciences
  • Author:

    Hannah Wastyk

    Chief Executive Officer
    Interface Biosciences

    Hannah Wastyk

    Chief Executive Officer
    Interface Biosciences
  • Author:

    Jeffrey Zhao

    Chief Executive Officer
    Notitia Biotechnologies

    Jeffrey Zhao

    Chief Executive Officer
    Notitia Biotechnologies
  • Author:

    Sam Possemiers

    Chief Executive Officer
    MRM Health

    Sam Possemiers

    Chief Executive Officer
    MRM Health
  • Author:

    Tonya Ward

    Senior Director, Microbiome Data Science
    Rebiotix Inc., a Ferring Company

    Tonya Ward

    Senior Director, Microbiome Data Science
    Rebiotix Inc., a Ferring Company
  • Author:

    Peter Nara

    Chief Scientific Officer
    Keystone Bio

    Dr. Nara is currently on of the co-founders, the Chief Scientific Officer and President Business Development for Keystone Bio Inc. in St. Louis, Mo., a Systemic-Oral Health Biomedical company that is targeting precision microbiome bio-therapeutics for the elimination of a specific oral bacterial associated with systemic inflammation. He is also the former co-founder, President, Chairman and CEO (1997-2017)and now Chairman Emeritus at Biological Mimetics, Inc. and cofounder of Lantern Pharma Inc. He holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D. (retro-virology/oncogenesis) from The Ohio State University, 4 year combined residency in Comparative Pathology and NIH post-doctoral Fellowship at the Armed Forces Institute of Pathology and a NIH respectively. Dr. Nara currently holds the Endowed Eugene Lloyd Chair, Professor in Vaccinology, founding Center Director for the Center for Advanced Host Defense, Immunobiotics, and Translational Comparative Medicine in the Department of Biomedical Sciences, in the College of Veterinary Medicine at Iowa State University and also the Chief Executive Officer, President, Chairman & co-founder of Biological Mimetics, Inc.,. He is also an distinguished Alumni of The Ohio State University College of Veterinary Medicine 2014, and an elected Fellow of the American Association for the Advancement of Science in 2011. His comparative medical research interests are to more fully understand how early and pre-determined events in the host innate and acquired immune systems are sculpted and bias the development of protective long lasting responses against infectious pathogens and cancer. More importantly  he and his team are interested developing new technologies and strategies to circumvent the non-protective immune responses for the development of novel classes of immunobiotics and vaccines focused on the prevention of disease and are translating these into viably products via a new academic- private-commercial model. He has been and continues as National and International member of numerous programs at the National Academy of Science, Institutes of Medicine, National Institutes of Health, Department of Defense, and Centers for Disease Control AIDS, World Health Organization, United Nations Global AIDS Characterization program–related and infectious diseases national planning, human and animal agricultural biodefense, vaccine development & policy reporting meetings involving pathogenesis, vaccine discovery, standardization, correlates of protection committees and consults and serves on numerous scientific advisory boards of corporate, private foundations and academic initiatives in the area of national biodefense, comparative medicine and immunology, vaccine discovery and immuno-therapeutics and a recent member of the U.S. State Department Bio-Industry Initiative Program, The Civilian Research and Development Foundation (CDRF) and The International Science and Technology Center (ISTC) for non-proliferation of biological agents.

     

    Peter Nara

    Chief Scientific Officer
    Keystone Bio

    Dr. Nara is currently on of the co-founders, the Chief Scientific Officer and President Business Development for Keystone Bio Inc. in St. Louis, Mo., a Systemic-Oral Health Biomedical company that is targeting precision microbiome bio-therapeutics for the elimination of a specific oral bacterial associated with systemic inflammation. He is also the former co-founder, President, Chairman and CEO (1997-2017)and now Chairman Emeritus at Biological Mimetics, Inc. and cofounder of Lantern Pharma Inc. He holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D. (retro-virology/oncogenesis) from The Ohio State University, 4 year combined residency in Comparative Pathology and NIH post-doctoral Fellowship at the Armed Forces Institute of Pathology and a NIH respectively. Dr. Nara currently holds the Endowed Eugene Lloyd Chair, Professor in Vaccinology, founding Center Director for the Center for Advanced Host Defense, Immunobiotics, and Translational Comparative Medicine in the Department of Biomedical Sciences, in the College of Veterinary Medicine at Iowa State University and also the Chief Executive Officer, President, Chairman & co-founder of Biological Mimetics, Inc.,. He is also an distinguished Alumni of The Ohio State University College of Veterinary Medicine 2014, and an elected Fellow of the American Association for the Advancement of Science in 2011. His comparative medical research interests are to more fully understand how early and pre-determined events in the host innate and acquired immune systems are sculpted and bias the development of protective long lasting responses against infectious pathogens and cancer. More importantly  he and his team are interested developing new technologies and strategies to circumvent the non-protective immune responses for the development of novel classes of immunobiotics and vaccines focused on the prevention of disease and are translating these into viably products via a new academic- private-commercial model. He has been and continues as National and International member of numerous programs at the National Academy of Science, Institutes of Medicine, National Institutes of Health, Department of Defense, and Centers for Disease Control AIDS, World Health Organization, United Nations Global AIDS Characterization program–related and infectious diseases national planning, human and animal agricultural biodefense, vaccine development & policy reporting meetings involving pathogenesis, vaccine discovery, standardization, correlates of protection committees and consults and serves on numerous scientific advisory boards of corporate, private foundations and academic initiatives in the area of national biodefense, comparative medicine and immunology, vaccine discovery and immuno-therapeutics and a recent member of the U.S. State Department Bio-Industry Initiative Program, The Civilian Research and Development Foundation (CDRF) and The International Science and Technology Center (ISTC) for non-proliferation of biological agents.

     

  • Author:

    Julius Goepp

    Chief Scientific Officer
    Evimero

    Julius Goepp

    Chief Scientific Officer
    Evimero
  • Author:

    Gabriel Levanthal

    Chief Scientific Officer
    PharmaBiome

    Gabriel Levanthal

    Chief Scientific Officer
    PharmaBiome
  • Author:

    Todd Krueger

    President & CEO
    AOBiome

    Todd Krueger

    President & CEO
    AOBiome
  • Author:

    Cassandra Isley

    Founder
    Microbiome Alliance for Disease Prevention

    Cassandra Isley

    Founder
    Microbiome Alliance for Disease Prevention
  • Author:

    Jun Terauchi

    Steering Committee Chair
    Japan Microbiome Consortium

    Jun Terauchi

    Steering Committee Chair
    Japan Microbiome Consortium
  • Author:

    Becca Senter

    Vice President and Head of Preclinical Research and Development
    Axial Therapeutics

    Becca Senter

    Vice President and Head of Preclinical Research and Development
    Axial Therapeutics
  • Author:

    Mary Poor

    Vice President of Quality and CMC
    Siolta Therapeutics

    Mary Poor

    Vice President of Quality and CMC
    Siolta Therapeutics
  • Author:

    Kyongsub Song

    Chief Technology Officer
    LISCure Biosciences

    Kyongsub Song

    Chief Technology Officer
    LISCure Biosciences
  • Author:

    Alicia Szretter

    Director, CMC Operations
    Vedanta Bio

    Alicia Szretter

    Director, CMC Operations
    Vedanta Bio
  • Author:

    Russel Wyborski

    Director, Ventures
    Crohns and Colitis Foundation

    Russel Wyborski

    Director, Ventures
    Crohns and Colitis Foundation
  • Author:

    Nicolas Pichon

    Head of Manufacturing
    Servatus

    Nicolas Pichon

    Head of Manufacturing
    Servatus
  • Author:

    Bob Hettich

    Professor
    Oak Ridge National Laboratory

    Bob Hettich

    Professor
    Oak Ridge National Laboratory
  • Author:

    Craig Cohen

    Professor
    University of California San Francisco

    Craig Cohen

    Professor
    University of California San Francisco
  • Author:

    Tagbo Niepa

    Associate Professor of Chemical Engineering
    Carnegie Mellon University

    Tagbo Niepa

    Associate Professor of Chemical Engineering
    Carnegie Mellon University
  • Author:

    Andrea Facciabene

    Associate Professor
    University of Pennsylvania

    Andrea Facciabene

    Associate Professor
    University of Pennsylvania
  • Author:

    Caleb Bell

    Venture Partner
    CSB

    Caleb Bell

    Venture Partner
    CSB
  • Author:

    Laurel Lagenaur

    Head of Research
    Osel

    Laurel Lagenaur

    Head of Research
    Osel
  • Author:

    Nik Sharma

    Chief Executive Officer
    BioCortex

    Nik Sharma

    Chief Executive Officer
    BioCortex
  • Author:

    Daniel van der Lelie

    Chief Executive Officer
    Gusto Global

    Daniel van der Lelie

    Chief Executive Officer
    Gusto Global
  • Author:

    Carole Schwintner

    Chief Technical Officer
    MaaT Pharma

    Carole Schwintner

    Chief Technical Officer
    MaaT Pharma
  • Author:

    Akshata Udyavar

    Senior Director Immunology and Translational Sciences
    Actym

    Akshata Udyavar

    Senior Director Immunology and Translational Sciences
    Actym
  • Author:

    James Morton

    Simons Foundation

    James Morton

    Simons Foundation
  • Author:

    Vivek Lal

    Chief Scientific Officer
    Alveolus Bio

    Vivek Lal

    Chief Scientific Officer
    Alveolus Bio
  • Author:

    Cheri Ackerman

    CEO
    Concerto Biosciences

    Cheri Ackerman

    CEO
    Concerto Biosciences
  • Author:

    Lorenz Rindisbacher

    Chief Quality Officer
    Bacthera

    Lorenz Rindisbacher

    Chief Quality Officer
    Bacthera
  • Author:

    Neil Stollman

    Chairman, Division of Gastroenterology
    Sutter Health

    Neil Stollman

    Chairman, Division of Gastroenterology
    Sutter Health
  • Author:

    Ryan Wilson

    Head of LBT
    SGS-Quay Pharma

    Ryan Wilson

    Head of LBT
    SGS-Quay Pharma
  • Author:

    Bernat Olle

    CEO
    Vedanta Biosciences

    Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of several companies of the PureTech portfolio and served as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences.

     

    In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in the Republic of Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.

    Bernat Olle

    CEO
    Vedanta Biosciences

    Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of several companies of the PureTech portfolio and served as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences.

     

    In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in the Republic of Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.

  • Author:

    Amine Zorgani

    Founder
    Microbiome Mavericks

    Amine Zorgani

    Founder
    Microbiome Mavericks
  • Author:

    Felix Faupel

    Chief Commercial Officer
    Bacthera

    Felix Faupel

    Chief Commercial Officer
    Bacthera
  • Author:

    Sonia Timberlake

    Former SVP of Research
    Finch Therapeutics

    Sonia is the Senior Vice President of Research at Finch Therapeutics. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology. 

     

    Sonia graduated from Caltech with a B.Sc in Molecular Biology and received her Ph.D. in Biological Engineering from MIT. 

    Sonia Timberlake

    Former SVP of Research
    Finch Therapeutics

    Sonia is the Senior Vice President of Research at Finch Therapeutics. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology. 

     

    Sonia graduated from Caltech with a B.Sc in Molecular Biology and received her Ph.D. in Biological Engineering from MIT. 

  • Author:

    Jason Ryan

    Head of Scientific Development
    Sacco System

    Jason Ryan

    Head of Scientific Development
    Sacco System
  • Author:

    Anders Gron

    Chief Executive Officer
    CosmosID, Clinical Microbiomics

    Anders Gron

    Chief Executive Officer
    CosmosID, Clinical Microbiomics
  • Author:

    Yvonne Nyavor

    Principal Scientist, Microbiome
    Boston Analytical

    Yvonne Nyavor

    Principal Scientist, Microbiome
    Boston Analytical
  • Author:

    Jeffrey Heiser

    Chief Scientific Officer
    Boston Analytical

    Jeffrey Heiser

    Chief Scientific Officer
    Boston Analytical
  • Author:

    Melanie Eldridge

    Head of Microbiome Sciences
    Arranta Bio / ReciBioPharm

    Melanie Eldridge

    Head of Microbiome Sciences
    Arranta Bio / ReciBioPharm

Commercial, Collaboration and Investment Speakers

 

Moreno Perugini

President Pharma
Nestle Health Sciences

Moreno Perugini

President Pharma
Nestle Health Sciences

Moreno Perugini

President Pharma
Nestle Health Sciences
 

Terri Young

Executive Vice President, Chief Commercial and Strategy Officer
Seres Therapeutics

Terri Young

Executive Vice President, Chief Commercial and Strategy Officer
Seres Therapeutics

Terri Young

Executive Vice President, Chief Commercial and Strategy Officer
Seres Therapeutics
 

Daniel Cuoto

Chief Operating Officer
Vedanta Bio

Daniel Cuoto

Chief Operating Officer
Vedanta Bio

Daniel Cuoto

Chief Operating Officer
Vedanta Bio
 

Andrew Nealon

Partner and Chief Analyst
Joyance

Andrew Nealon

Partner and Chief Analyst
Joyance

Andrew Nealon

Partner and Chief Analyst
Joyance
 

Caleb Bell

Venture Partner
CSB

Caleb Bell

Venture Partner
CSB

Caleb Bell

Venture Partner
CSB
 

Denise Kelly

Investment Advisor
Seventure Partners

Denise Kelly

Investment Advisor
Seventure Partners

Denise Kelly

Investment Advisor
Seventure Partners
 

Elran Haber, PhD

Chief Executive Officer
Biomica

Elran Haber, PhD

Chief Executive Officer
Biomica

Elran Haber, PhD

Chief Executive Officer
Biomica
 

Cassandra Isley

Founder
Microbiome Alliance for Disease Prevention

Cassandra Isley

Founder
Microbiome Alliance for Disease Prevention

Cassandra Isley

Founder
Microbiome Alliance for Disease Prevention
 

Jun Terauchi

Steering Committee Chair
Japan Microbiome Consortium

Jun Terauchi

Steering Committee Chair
Japan Microbiome Consortium

Jun Terauchi

Steering Committee Chair
Japan Microbiome Consortium
 

Jacquelin Gaulin

Founder
Gastro Girl Inc. and Host of Gastro Girl Podcast

Jacquelin Gaulin

Founder
Gastro Girl Inc. and Host of Gastro Girl Podcast

Jacquelin Gaulin

Founder
Gastro Girl Inc. and Host of Gastro Girl Podcast
 

Russel Wyborski

Director, Ventures
Crohns and Colitis Foundation

Russel Wyborski

Director, Ventures
Crohns and Colitis Foundation

Russel Wyborski

Director, Ventures
Crohns and Colitis Foundation
 

Neil Stollman

Chairman, Division of Gastroenterology
Sutter Health

Neil Stollman

Chairman, Division of Gastroenterology
Sutter Health

Neil Stollman

Chairman, Division of Gastroenterology
Sutter Health
 

Paul Moayyedi

Professor, Medicine
McMaster University

Paul Moayyedi

Professor, Medicine
McMaster University

Paul Moayyedi

Professor, Medicine
McMaster University

Therapeutic and R&D Speakers

 

Ken Blount

VP of Microbiome Research, Ferring Pharmaceuticals, and CSO, Rebiotix Inc., a Ferring Company

Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center.

Ken Blount

VP of Microbiome Research, Ferring Pharmaceuticals, and CSO, Rebiotix Inc., a Ferring Company

Ken Blount

VP of Microbiome Research, Ferring Pharmaceuticals, and CSO, Rebiotix Inc., a Ferring Company

Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.

 

Hervé Affagard

Chief Executive Officer
MaaT Pharma

Hervé Affagard

Chief Executive Officer
MaaT Pharma

Hervé Affagard

Chief Executive Officer
MaaT Pharma
 

Nikole Kimes

Chief Executive Officer
Siolta Therapeutics

Nikole Kimes

Chief Executive Officer
Siolta Therapeutics

Nikole Kimes

Chief Executive Officer
Siolta Therapeutics
 

Benjamin Hadida

Chief Executive Officer
Exeliom Biosciences

Benjamin Hadida

Chief Executive Officer
Exeliom Biosciences

Benjamin Hadida

Chief Executive Officer
Exeliom Biosciences
 

Jeffrey Zhao

Chief Executive Officer
Notitia Biotechnologies

Jeffrey Zhao

Chief Executive Officer
Notitia Biotechnologies

Jeffrey Zhao

Chief Executive Officer
Notitia Biotechnologies
 

Sam Possemiers

Chief Executive Officer
MRM Health

Sam Possemiers

Chief Executive Officer
MRM Health

Sam Possemiers

Chief Executive Officer
MRM Health
 

Peter Nara

CSO
Keystone Bio Inc.

Dr. Nara is currently on of the co-founders, the Chief Scientific Officer and President Business Development for Keystone Bio Inc. in St. Louis, Mo., a Systemic-Oral Health Biomedical company that is targeting precision microbiome bio-therapeutics for the elimination of a specific oral bacterial associated with systemic inflammation. He is also the former co-founder, President, Chairman and CEO (1997-2017)and now Chairman Emeritus at Biological Mimetics, Inc. and cofounder of Lantern Pharma Inc. He holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D.

Peter Nara

CSO
Keystone Bio Inc.

Peter Nara

CSO
Keystone Bio Inc.

Dr. Nara is currently on of the co-founders, the Chief Scientific Officer and President Business Development for Keystone Bio Inc. in St. Louis, Mo., a Systemic-Oral Health Biomedical company that is targeting precision microbiome bio-therapeutics for the elimination of a specific oral bacterial associated with systemic inflammation. He is also the former co-founder, President, Chairman and CEO (1997-2017)and now Chairman Emeritus at Biological Mimetics, Inc. and cofounder of Lantern Pharma Inc. He holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D. (retro-virology/oncogenesis) from The Ohio State University, 4 year combined residency in Comparative Pathology and NIH post-doctoral Fellowship at the Armed Forces Institute of Pathology and a NIH respectively. Dr. Nara currently holds the Endowed Eugene Lloyd Chair, Professor in Vaccinology, founding Center Director for the Center for Advanced Host Defense, Immunobiotics, and Translational Comparative Medicine in the Department of Biomedical Sciences, in the College of Veterinary Medicine at Iowa State University and also the Chief Executive Officer, President, Chairman & co-founder of Biological Mimetics, Inc.,. He is also an distinguished Alumni of The Ohio State University College of Veterinary Medicine 2014, and an elected Fellow of the American Association for the Advancement of Science in 2011. His comparative medical research interests are to more fully understand how early and pre-determined events in the host innate and acquired immune systems are sculpted and bias the development of protective long lasting responses against infectious pathogens and cancer. More importantly  he and his team are interested developing new technologies and strategies to circumvent the non-protective immune responses for the development of novel classes of immunobiotics and vaccines focused on the prevention of disease and are translating these into viably products via a new academic- private-commercial model. He has been and continues as National and International member of numerous programs at the National Academy of Science, Institutes of Medicine, National Institutes of Health, Department of Defense, and Centers for Disease Control AIDS, World Health Organization, United Nations Global AIDS Characterization program–related and infectious diseases national planning, human and animal agricultural biodefense, vaccine development & policy reporting meetings involving pathogenesis, vaccine discovery, standardization, correlates of protection committees and consults and serves on numerous scientific advisory boards of corporate, private foundations and academic initiatives in the area of national biodefense, comparative medicine and immunology, vaccine discovery and immuno-therapeutics and a recent member of the U.S. State Department Bio-Industry Initiative Program, The Civilian Research and Development Foundation (CDRF) and The International Science and Technology Center (ISTC) for non-proliferation of biological agents.

 

Daniel van der Lelie

Chief Executive Officer
Gusto Global

Daniel van der Lelie

Chief Executive Officer
Gusto Global

Daniel van der Lelie

Chief Executive Officer
Gusto Global
 

Todd Krueger

President & CEO
AOBiome

Todd Krueger

President & CEO
AOBiome

Todd Krueger

President & CEO
AOBiome
 

Becca Senter

Vice President and Head of Preclinical Research and Development
Axial Therapeutics

Becca Senter

Vice President and Head of Preclinical Research and Development
Axial Therapeutics

Becca Senter

Vice President and Head of Preclinical Research and Development
Axial Therapeutics
 

Kyongsub Song

Chief Technology Officer
LISCure Biosciences

Kyongsub Song

Chief Technology Officer
LISCure Biosciences

Kyongsub Song

Chief Technology Officer
LISCure Biosciences
 

Akshata Udyavar

Senior Director Immunology and Translational Sciences
Actym

Akshata Udyavar

Senior Director Immunology and Translational Sciences
Actym

Akshata Udyavar

Senior Director Immunology and Translational Sciences
Actym
 

Craig Cohen

Professor
University of California San Francisco

Craig Cohen

Professor
University of California San Francisco

Craig Cohen

Professor
University of California San Francisco
 

Caroline Mitchell

Professor
Harvard University

Caroline Mitchell

Professor
Harvard University

Caroline Mitchell

Professor
Harvard University
 

Andrea Facciabene

Associate Professor
University of Pennsylvania

Andrea Facciabene

Associate Professor
University of Pennsylvania

Andrea Facciabene

Associate Professor
University of Pennsylvania
 

Ellen Turner

Medical Officer
FDA - Center for Biologics Evaluation and Research, Office of Vaccines Research

Ellen Turner

Medical Officer
FDA - Center for Biologics Evaluation and Research, Office of Vaccines Research

Ellen Turner

Medical Officer
FDA - Center for Biologics Evaluation and Research, Office of Vaccines Research
 

Laurel Lagenaur

Head of Research
Osel

Laurel Lagenaur

Head of Research
Osel

Laurel Lagenaur

Head of Research
Osel
 

Lital Gilad-Shaoulian

Chief Executive Officer
PurposeBio

Lital Gilad-Shaoulian

Chief Executive Officer
PurposeBio

Lital Gilad-Shaoulian

Chief Executive Officer
PurposeBio
 

Cheri Ackerman

CEO
Concerto Biosciences

Cheri Ackerman

CEO
Concerto Biosciences

Cheri Ackerman

CEO
Concerto Biosciences

Data Strategy Speakers

 

Oliver Weisser

Director, Commercial Operations
Ginkgo Bioworks

Oliver Weisser

Director, Commercial Operations
Ginkgo Bioworks

Oliver Weisser

Director, Commercial Operations
Ginkgo Bioworks
 

Hannah Wastyk

Chief Executive Officer
Interface Biosciences

Hannah Wastyk

Chief Executive Officer
Interface Biosciences

Hannah Wastyk

Chief Executive Officer
Interface Biosciences
 

Julius Goepp

Chief Scientific Officer
Evimero

Julius Goepp

Chief Scientific Officer
Evimero

Julius Goepp

Chief Scientific Officer
Evimero
 

Bob Hettich

Professor
Oak Ridge National Laboratory

Bob Hettich

Professor
Oak Ridge National Laboratory

Bob Hettich

Professor
Oak Ridge National Laboratory
 

Tagbo Niepa

Associate Professor of Chemical Engineering
Carnegie Mellon University

Tagbo Niepa

Associate Professor of Chemical Engineering
Carnegie Mellon University

Tagbo Niepa

Associate Professor of Chemical Engineering
Carnegie Mellon University
 

James Morton

Simons Foundation

James Morton

Simons Foundation

James Morton

Simons Foundation